Clinical Trials | December 29, 2025
Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Adverse events were consistent with valbenazine’s established safety profile
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Subscribe To Our Newsletter & Stay Updated
